Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation
· Financial Post
TORONTO -- XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to the U.S. Food and Drug Administration (FDA) as part of the Pre-Market Approval (PMA) process later this year. Read More
Visit sportbet.rodeo for more information.